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PEMBANGUNAN PERPUSTAKAAN ANTIBODI PAPARAN FAJ 
FILARIASIS LIMFATIK MANUSIA DAN PENGHASILAN REKOMBINAN 
MONOKLONAL ANTIBODI TERHADAP ANTIGEN FILARIAL BmR1 DAN 
BmSXP 
 
ABSTRAK 
 
Program Penghapusan Filariasis Limfatik secara Global (GPELF) telah 
dilancarkan oleh WHO pada tahun 2000 untuk menghapuskan penyakit ini sebagai 
masalah kesihatan awam menjelang tahun 2020. Brugia Rapid dan PanLF Rapid 
merupakan diagnostik pantas yang digunakan dalam program ini di kawasan endemik 
filariasis brugian. Kedua-dua ujian ini berdasarkan pengesanan antibodi terhadap 
protein rekombinan BmR1 dan BmSXP. Memandangkan GPELF sedang berkembang 
ke arah fasa pengakhiran yang melibatkan pengawasan pasca-MDA dan pasca-
pengesahan, ujian pantas dengan kepekaan diagnostik yang lebih tinggi daripada yang 
ada sekarang adalah diperlukan. Dalam hal ini, pendekatan yang diambil adalah 
dengan menggunakan antigen rekombinan yang berketulen tinggi untuk membolehkan 
penggunaan jumlah antigen yang meningkat tanpa mengurangkan spesifikasi ujian. 
Ketersediaan monoklonal antibodi rekombinan terhadap dua protein rekombinan ini 
adalah sangat berguna dalam menghasilkan antigen berketulenan tinggi. Peringkat 
awal kajian ini melibatkan pembangunan perpustakaan scFv filariasis limfatik manusia 
menggunakan teknologi paparan faj. Perpustakaan dihasilkan menggunakan sistem 
berasaskan perantara TA untuk pengklonan, dan kepelbagaian perpustakaan yang 
dicapai adalah 108. Kemudian antibodi monoklonal diasingkan melalui proses 
“biopanning” menggunakan perpustakaan imun yang baru dibina dan perpustakaan 
naif yang dihasilkan dalam makmal. Bagi perpustakaan imun, enam dan dua antibodi 
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monoclonal, masing-masing kepada BmSXP dan BmR1 telah diasingkan. Bagi 
perpustakaan naif pula, dua antibodi monoklonal untuk setiap protein rekombinan 
telah diasingkan. Semua antibodi monoklonal dicirikan berdasarkan penggunaan V-
gen mereka, pasangan gen, panjang CDR, taburan asid amino, arah kutuban dan 
kedudukan. Keputusan menunjukkan bahawa perpustakaan imun mempunyai 
perwakilan gen keluarga dari kappa dan lambda, manakala hanya klon keluarga 
lambda yang berjaya diasingkan daripada perpustakaan naif. Keputusan ujian 
kompetitif ELISA menunjukkan bahawa terdapat klon yang bersaing untuk tapak 
ikatan yang sama, dengan itu ia melekat pada tapak epitope yang sama pada antigen. 
Selanjutnya klon-klon antibodi yang digunakan untuk titrasi kepekatan antibodi oleh 
ELISA adalah 5B, 4F, 3A dan 4, 20 untuk antigen BmSXP dan BmR1 bagi 
perpustakaan imun; manakala klon-klon antibodi yang terpilih dari perpustakaan naif 
adalah XP_D5, XP_B6 dan H4R1, GIR1 masing-masing untuk antigen BmSXP dan 
BmR1. Kesemua klon antibodi menunjukkan had pengikatan yang berbeza, namun 
antibodi monoklonal 5B dan 4 menunjukkan keupayaan pengikatan yang tinggi pada 
kepekatan antigen yang rendah iaitu 1 pg dan 100 pg, masing-masing untuk BmSXP 
dan BmR1. Akhirnya, klon antibodi 5B, 3A dan 4, 20 dipilih, masing-masing untuk 
pembangunan kolum afiniti bagi penulenan BmSXP dan BmR1. Bagi penulenan 
antigen BmSXP, kolum antibodi campuran didapati lebih baik daripada kolum 
antibodi tunggal. Manakala bagi penulenan antigen BmR1 pula, kolum antibodi 
tunggal memberi hasil yang lebih baik. Antibodi monoklonal 5B telah dikonjugasikan 
dengan nanopartikel emas dan ia menunjukkan reaktiviti yang baik dengan ujian 
dipstik aliran sisi antigen BmSXP, serta didapati tidak reaktif apabila diuji dengan 
ujian dipstik aliran sisi BmR1. Kesimpulannya, kajian ini telah berjaya menghasilkan 
sebuah perpustakaan filariasis limfatik manusia yang baru dan antibodi monoklonal 
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terhadap antigen BmSXP dan BmR1. Seterusnya, kolum antibodi afiniti untuk 
penulenan BmSXP dan BmR1 juga telah dibangunkan dan dinilai serta antibodi 
monoklonal terhadap antigen BmSXP telah berjaya dikonjugasikan kepada emas dan 
diaplikasikan dalam ujian dipstik aliran sisi. 
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CONSTRUCTION OF HUMAN LYMPHATIC FILARIASIS ANTIBODY 
PHAGE DISPLAY LIBRARY AND PRODUCTION OF RECOMBINANT 
MONOCLONAL ANTIBODIES AGAINST BmR1 AND BmSXP FILARIAL 
ANTIGENS 
 
ABSTRACT 
 
A Global Programme for Elimination of Lymphatic Filariasis aims to eliminate 
the disease as a public health problem by the year 2020. Brugia Rapid and PanLF 
Rapid are rapid diagnostic tools that are being used in this programme. They are based 
on the detection of recombinant proteins BmR1 and BmSXP. The quality of these tests 
should be well-maintained at all time or even improved as the GPELF progresses and 
a sensitive and specific test may be needed at the end of the programme and for 
surveillance post-certification. To address this need, the availability of recombinant 
monoclonal antibodies to the two recombinant proteins would be very useful. The first 
objective of this study involved the construction of a human lymphatic filariasis scFv 
library using phage display technology. The library was generated using a TA based 
intermediate shuttle system for cloning and the diversity of the library was 108. Then 
monoclonal antibodies were isolated via biopanning using the newly constructed 
immune library and an in-house produced naïve library. From the immune library six 
and two monoclonal antibodies to BmSXP and BmR1, respectively were isolated. 
From the naïve library two monoclonal antibodies to each recombinant protein were 
isolated. All the monoclonal antibodies were characterized based on their V-gene 
usage, gene pairing, CDR length, amino acid distribution, polarity and position. The 
results showed that the immune library has both kappa and lambda family gene 
representation, however only lambda family clones were isolated from the naïve 
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library. The result of cross-reactivity showed that there were clones competing for the 
same binding site, thus had bound to the same epitope of the antigen. Subsequently the 
clones used for titrations of the antibody concentrations by ELISA were 5B, 4F, 3A 
and 4, 20 for BmSXP and BmR1 antigens for immune library; while the selected 
antibody clones from naïve library were XP_D5, XP_B6 and H4R1, GIR1 for BmSXP 
and BmR1 antigens respectively. All the antibody clones showed different binding 
limits, however monoclonal antibody 5B and 4 showed high ability to bind at low 
antigen concentration: 1 pg and 100 pg for BmSXP and BmR1, respectively. Finally, 
antibody clones 5B, 3A and 4, 20 were selected for development of affinity columns 
for purification of BmSXP and BmR1 antigens. For purification of the BmSXP antigen, 
the ‘mixture antibody column’ performed better than ‘single antibody column’. 
Meanwhile, single antibody column worked better for purification of the BmR1 
antigen. Monoclonal antibody 5B was conjugated with gold nanoparticles and it 
showed good reactivity with a dipstick test lined with BmSXP antigen and not reactive 
with a dipstick lined with BmR1. In conclusion, this study has successfully produced 
a novel human lymphatic filariasis library and monoclonal antibodies against BmSXP 
and BmR1 antigens. Affinity antibody columns for BmSXP and BmR1 purifications 
were developed and gold conjugated monoclonal antibody against BmSXP antigen 
was successfully applied in a lateral flow dipstick test.  
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Lymphatic filariasis: An overview 
Lymphatic filariasis (LF), or more commonly known as elephantiasis is a mosquito-
borne parasitic disease caused by three species of tissue dwelling filaroid nematodes 
that live in the human lymphatic system. This disease is widely prevalent in 
populations living in tropical and sub-tropical regions of the world, such as Asia, 
Africa, Central and South America. Latest report from the World Health Organization 
(WHO) stated that around 947 million people in 54 countries worldwide are threatened 
by LF and they need immediate treatments to stop the spread of the infection 
(http://www.who.int/mediacentre/factsheets/fs102/en/). The infection usually 
acquired in early childhood and in charge for considerable morbidity, causing social 
stigma among children, women and men (Pandey et al., 2011). 
 WHO has listed LF as one of the neglected tropical diseases (NTDs) among 16 
other diseases (http://www.who.int/neglected_diseases/diseases/en/). These diseases 
have been ranked low on national and international agenda because most of the 
developed parts of the world successfully wiped out the infection. Meanwhile, these 
diseases only persist in the poorest, most marginalised communities. The outcome of 
the disease causes tremendous but hidden suffering due to their disfiguring, 
debilitating and sometimes fatal impact. There is little incentive for the industry to 
develop products for diseases linked with poverty. Thus, despite the need for better 
treatment and prevention is huge, the affected populations have limited access to them.
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In 2000, WHO initiated a global programme for elimination of the disease 
known as the ‘Global Programme to Eliminate Lymphatic Filariasis’ (GPELF) and has 
identified it to be one of the six infectious diseases that has the potential to be 
eliminated as a public health problem (WHO, 1998). Two major aims of this 
programme is to interrupt transmission of the parasite and morbidity control by 
providing care for those who suffer the devastating clinical manifestations of the 
disease (Addiss and Brady, 2007). The choice of diagnostic tool plays an important 
role in GPELF because it affects the decision of treatment. Thus, various types of 
diagnostic tolls have been suggested at different phases of GPELF, such as 
parasitological diagnosis, rapid antigen and antibody tests and molecular diagnostics 
(Weil and Ramzy, 2007). However, the outmost pivotal diagnostic tool is a field-
applicable tool that produces rapid results and allows for timely programmatic 
decisions to be made. Besides, diagnostic assays based on antibody and antigen have 
been proven to be very useful in the early identification of filarial infections (Pandey 
et al., 2011). Examples of commercial tests used are the ICT Filariasis NOWTM, 
Og4C3-ELISA, Brugia Rapid and Pan LF Rapid. 
 Although much emphasis and improvement in the diagnosis of filariasis had 
been highlighted over more than a decade ago, the evaluation of current research and 
challenges in overcoming helminth diseases found major deficiencies in control tools, 
diagnostics, fundamental knowledge and biology of helminth (WHO, 2012). Thus, 
challenges to eliminate LF still exist.  
 
1.2 History of discovery: Lymphatic filariasis and microfilariae 
There is no clear written record on historical evidence of LF. Ancient artifacts showing 
the symptoms of LF infection such as a statue of Pharaoh Mentuhotep II depicts 
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swollen limbs and the Nok civilization in West Africa showing scrotal swelling 
suggest that the disease may have been present as early as 2000 BC. 
(https://web.stanford.edu/class/humbio103/ParaSites2006/Lymphatic_filariasis/). 
Microfilariae was associated with elephanthiasis by Jean Nicolas Demarquay in 1863, 
when he recorded microfilaria in the milky fluid extracts from hydrocele of a Cuban 
patient in Paris. This was followed by Otto Henry Wucherer in 1866 who found 
microfilaria in urine, and subsequently Timothy Lewis found microfilaria in blood in 
1872 (Otsuji, 2011).  
 Then in 1877, Joseph Bancroft documented adult worm while examining the 
fluid extracted from an abscess on a patient’s arm and it was called as Filaria bancrofti. 
The most important discovery was made by Patrick Manson in 1877, where he found 
microfilariae in the stomach of blood sucking mosquito and pin-pointed mosquito as 
the intermediate host. This discovery was considered as the birth of medical 
entomology and later was applied to other tropical diseases such as malaria. It was 
only in 1921 that the name Wuchereria bancrofti (W. bancrofti) was accepted. New 
species of microfilariae was discovered in parts of Indonesia by Lichtenstein in 1927. 
The new species was noticed to be different than the earlier found worm and in 1960 
Buckley suggested to name it as Brugia malayi (B. malayi). Later new species of 
Brugia was found Timor Island and it is named as Brugia timori (B. timori). 
 The life cycle of LF was initially wrongly hypothesized by Manson that the 
disease is transmitted to human after the ingestion of contaminated water or direct skin 
penetration with water in which the mosquitoes had laid eggs. Only in 1900, the actual 
mechanism of transmission was revealed by George Carmichael Low when he 
discovered microfilariae in the proboscis of the mosquito vector.  
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1.3 The filaria organism 
1.3.1 Taxanomy  
Filarial worms are classified under the family of Filarioidea of nematodes and the 
genus of Brugia. There are eight important species of filarial worms which use humans 
as the host and they are divided into three groups. Lymphatic filariasis is caused by 
the W. bancrofti, B. malayi, and B. timori. Cutaneous filariasis is caused by Loa loa 
also called as the African eye worm, Mansonella streptocerca and Onchocerca 
volvulus. Body cavity filariasis is caused by Mansonella perstans and Mansonella 
ozzardi. Most cases of filariasis in humans worldwide are caused by W. bancrofti 
(https://www.cdc.gov/parasites/lymphaticfilariasis/).  
 
1.3.2 Morphology of lymphatic filarial worms 
Differences among the three LF worms reside in vectors, epidemiology, reservoirs, 
symptoms, and mainly species morphology. W. bancrofti has the most significant 
difference in morphology compared to other species and it is also the most well 
documented species. It exhibits sexual dimorphism and it is hard to be removed from 
tissues due to their delicate body. The adult worm is long, cylindrical, slender, and 
smooth with rounded ends. The worm appears in white in colour and almost 
transparent. The sheathed microfilariae (larvae) of W. bancrofti measures 245 to 300 
µm. and it take several months to sexually mature. The male worm measures 40 mm 
in length and by 100 μm in width. In contrast, the female worm is three times larger in  
diameter than the male worm with 60 mm to 100 mm in length and 300 μm width. One 
end of the round body is blunt, while the other is pointed (Figure 1.1a).  
On the other hand, the B. malayi male worm measures 13 to 23 mm in length 
by 70 to 80 μm in width and the female worm measures 43 to 55 mm in length by 130 
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to 170 μm in width. Adult worms produce microfilariae, measuring 177 to 230 μm in 
length and 5 to 7 μm in width (Figure 1.1b) (https://web.stanford.edu/class /humbio 
103/ParaSites2006/Lymphaticfilariasis/). 
The nuclei of B. malayi extends nearly to the tip of the tail while for W. 
bancrofti, the nuclei do not appear at the end of the tail. This is a major difference 
between these two species. Furthermore, both species lack a digestive system, instead 
absorbing nutrients from their hosts. The adult male and female worms inhabit 
primarily the lumen of lymphatics whereby the microfilariae usually migrate from the 
lymphatics into the blood stream (Nanduri and Kazura, 1989). 
 
1.3.3 Transmission and life cycle of lymphatic filaria 
The vector-borne disease is transmitted to human by the bite of more than 70 species 
and subspecies of infected mosquitoes mainly Anopheles, Aedes, Culex and Mansonia; 
(Stone et al., 1959; Nanduri and Kazura, 1989). All the three lymphatic filariae have 
similar biphasic life cycle where larval development takes place in mosquitoes 
(intermediate host) and adult development takes place in the human (definitive host). 
   
6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Lymphatic filariasis microfilariae worms. (a) Wuchereria bancrofti. (b)  
 Brugia malayi. 
 
Source: http://www.dpd.cdc.gov/dpdx/HTML/ImageLibrary/Filariasis_il.htm 
 
 
  
a 
b 
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The life cycle of lymphatic filariae consists of four different stages (L1-L4) as 
depicted in Figure 1.2. Mosquito ingests microfilariae during their feeding on an 
infected person (microfilaria carrier) as part of its blood meal. The microfilariae 
penetrate the mosquito’s gut wall and within a few hours they migrate to the flight 
muscles. There the microfilariae develop into three stages under optimum conditions 
of temperature and humidity. The L1 and L2 molt occur in 6 to 10 days then after 
several days, the parasite molt to the L3 parasite. The L3 then migrates from the flight 
muscles to the mouth parts of the vector, where they are positioned to be passed on to 
the host during a subsequent blood meal (Scott, 2000). 
The deposition of the third stage larvae (L3) on the skin of human (definitive 
host) following a bite by an infective mosquito initiates the infection. In human, the 
larval undergo an additional molt to the fourth larval stage (L4) between 9 to 14 days 
of post-infection as they mature into the lymphatic-dwelling adult male and female 
worms to complete the life cycle. The adult worms survive for around 5-8 years or 
sometimes up to 15 years or more. The lymphatic-dwelling filariae are diecious and 
undergo ovoviviparous reproduction resulting in the release of fully formed, sheathed 
first stage larvae (L1) from the female. Then, the microfilariae enter the peripheral 
circulation of the human host where they are available to be ingested by the vector 
during a blood meal (Scott, 2000).  In brugian filariasis, besides humans, other 
mammals such as domestic cat, Presbytis monkeys and wild mammals are the potential 
definitive host for the parasite (Mak, 1987). 
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Figure 1.2 The life cycle of Wuchereria bancrofti. 
 
Source: www.dpd.cdc.gov/dpdx 
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Microfilaria stage of the parasites show a unique characteristic which is they 
have “periodicity” that restricts their appearance in the blood to only certain periods 
of the day. They can be divided in two types of strains namely noctural periodic or as 
nocturnaly subperiodic. Nocturnally periodic strain microfilaria virtually disappears 
from the peripheral circulation and is found predominantly in the blood vessels of 
lungs and deep tissues during the daytime. Conversely, during the night time 
(especially between 10 pm until 2 am), it can be found in the peripheral blood. 
Meanwhile, for the nocturnally subperiodic strain, the microfilaria is mostly found at 
night and tend to lose their sheath in the process of dying on microscope slides 
(Bowman et al., 2002). In addition, there is also another microfilaria strain that is 
transmitted by day-biting mosquitoes of genus Aedes. It is called as non-periodic or 
diurnally subperiodic strain of microfilaria, but is limited to the South Pacific (Nanduri 
and Kazura, 1989).  
The periodicity characteristic in lymphatic filarial worms is due to the 
difference in the oxygen tension between the arterial and venous blood in the lungs 
(Hawking and Gammage, 1968; Burren, 1972; Nanduri and Kazura, 1989). However, 
it was suggested that these parasites have adapted their periodicity to the vector feeding 
behavior, possibly to facilitate their transmission (Nanduri and Kazura, 1989). 
 
1.3.4 Clinical manifestation 
Majority of the infected individuals who lives in LF endemic area fall into the 
following categories; asymptomatic amicrofilaraemia, symptomatic microfilaraemia, 
asymptomatic microfilaraemia, acute infection with filarial fever and 
adenolymphangitis (inflammation of the lymphatics and lymph nodes), chronic 
elephantiasis and occult filariasis. Asymptomatic amicrofilaraemia patients are the 
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infected individuals that do not exhibit any symptom and have no circulating 
microfilaria. Microfilaraemic patients are those with microfilaria circulating in their 
blood and these individuals may have symptoms (symptomatic) or have no physical 
symptoms (asymptomatic). In some cases, the asymptomatic individual may have 
hidden damage to their lymphatics, kidneys, and altered body's immune system. 
Individual with acute symptoms may suffer from recurrent attacks of fever with painful 
inflammation and swelling of the lymph glands or lymph channels. Chronic 
manifestations often affect the arms and legs and usually give rise to a condition of 
lymphoedema (tissue swelling) or elephantiasis (skin/tissue thickening). However, the 
clinical manifestations of LF varies geographically and species of the parasite. For 
example, in India subcontinent and Brazil where bancroftian filariasis is prevalent, the 
most common clinical form of the disease is tropical pulmonary eosinophilia while in 
parts of Africa is hydrocoele. Meanwhile, it is recognized that inguinal lymphadenitis 
and lymphangitis are more common in brugian filariasis with the exceptions of genital 
disease (hydrocoele and filarial scrotum) (Kumaraswami, 2000). 
 
1.3.5 Lymphatic filariasis in Malaysia 
The detection of microfilariae of the parasite in Malaysia has shown a lot of reduction 
with about 1,000 cases in 1987 to less than 300 in 2003, 172 cases in 2006 and 156 
cases in 2010. However, in 2011, about 387 microfilaria-positive cases were reported, 
with most new cases in Sabah and Sarawak (Malaysian Ministry of Health Annual 
Report, 2011).   
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B. malayi is the main species of parasite causing LF, and is mostly transmitted 
by mosquitoes belonging to the genus Mansonia, namely M. bonneae, M. dives, M. 
uniforms and M. Indiana (Chang et al., 1991; Kwa, 2008). However, in recent years 
the detection of W. bancrofti microfilaria positive cases has increased, and found 
mostly among migrant workers from Nepal, Myanmar, Bangladesh, Indonesia, India 
and Philippines (Malaysian Ministry of Health Annual Report, 2011). Thus, it is 
important to include the detection of bacroftian filariasis in an LF control or 
elimination programme in Malaysia. 
 
1.3.6 Diagnosis of lymphatic filariasis  
The diagnosis of LF can be divided into five methods as follows; microfilariae 
detection, filarial antigen detection, detection of specific antibodies, and radiological 
detection of adult worms.  
 
1.3.6(a) Microfilariae detection 
Microfilariae detection uses the thick blood smear technique. A drop of blood (50–60 
μl) is taken from a fingerprick and spread on a clean microscope slide, dried, stained 
and examined under the microscope for the presence of microfilariae. This method is 
simple and provides the definitive diagnosis in which the microfilariae can be 
visualised under the microscope. However, this method will probably have missed 
individuals with low microfilariae counts and those with amicrofilaremic infections. 
These individuals have the potential to contribute to future transmission. In addition, 
the phenomenon of microfilariae periodicity, which requires night blood collection are 
troublesome to the staff, villagers and impractical in some endemic areas (Weil and 
Ramzy, 2006). Subsequently, skilled personnels are needed to examine the 
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morphological features of the different species of lymphatic filariae. Modified 
methods such as Knott technique, membrane filtration or counting chamber improve 
the sensitivity of this method but are not practical to be performed at a large scale 
(Goldsmid, 1972; Melrose et al., 2000). 
 
1.3.6(b) Antigen detection 
Filarial antigen tests gain its entry in 1980 since then it has revolutionised the diagnosis 
of bancroftian filariasis. These tests are sensitive and specific because they do not 
require the presence of microfilariae, blood can be taken at any time and able to detect 
both the microfilaraemic and amicrofilaraemic cases. It is available in two formats, 
rapid card test and ELISA formats. The Binax NOW® Filariasis 
Immunochromatographic Test (ICT) is a rapid card test that uses capillary blood and 
give immediate result. This test has become one of the choices in diagnosis and the 
elimination programme (Phantana et al., 1999; Weil et al., 1997) but careful adherence 
to reading times is required to get accurate results (Simonsen and Dunyo, 1999). 
Recently an improved antigen test called Alere Filariasis test strip (FTS) was 
developed and showed better stability and sensitivity compared with the previous ICT. 
The TropBio ELISA test also called as the Og4C3 test has been reported to be more 
sensitive and convenient for laboratory and field-based study (Chanteau et al., 1994; 
More and Copeman, 1990; Simonsen and Dunyo, 1999). The microtitre plate is coated 
with Og4C3 (anti-filarial monoclonal antibody) and concentration of the circulating 
filarial antigen is determined using a standard curve. However, this test requires 
laboratory facilities, equipment and skilled personnel which limit its use in control 
programmes. To date there is no good antigen detection test for brugian filariasis. 
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1.3.6(c) Antibody detection 
Studies on antibody detection are mainly focused on IgG and IgG4 responses against 
the LF infection. Many studies have shown that anti-filarial IgG4 antibodies are able 
to detect active infection, particularly in children (Lal and Ottesen, 1988; Rahmah et 
al., 2001). Earlier report shows that the native antigen was useful for LF antibody 
detection but causes cross-reactivity with non-filaroid helminths. Therefore, 
recombinant antigens are preferred because they allow the production of a standardised 
assay and ensures the reproducibility of the test results. There are several recombinant 
antigens with good diagnostic values have been reported. The recombinant antigen test 
for brugian filariasis are BmR1 (Lammie et al., 2004; Rahmah et al., 2001) and Bm14 
(Weill et al., 2011) while for bancroftian filariasis are BmSXP (Noordin et al., 2007), 
WbSXP (Rao et al., 2000), Wb123 (Kubofcik, and Nutman, 2012) and Bm33 (Hamlin 
et al., 2012). Antibody testing appears to be more sensitive than antigen testing. There 
are two commercialized rapid tests available for detection of brugian LF which are 
based on detection of anti-filarial IgG4 antibody test namely Brugia Rapid and PanLF 
Rapid. Although there is an antigen detection test for bancroftian filariasis, antibody 
detection test is preferred for surveillance at the end of the LF elimination programme. 
 
1.3.6(d) DNA detection 
A number of molecular diagnostic assays such as Polymerase Chain Reaction (PCR), 
loop-mediated isothermal amplification (LAMP) and other techniques are being 
evaluated for LF detection but not yet available for routine use. These techniques are 
based on detection of specific DNA of lymphatic filarial species. There are several 
DNA targets have been used for LF detection, such as a highly conserved and 
repetitive 322 base pairs Hha1 DNA sequence. This is a common target for 
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conventional and real-time PCR assays and has been reported to be highly sensitive 
and specific for B. malayi detection (Fischer et al., 2000; Lizotte et al., 1994; Rahmah 
et al., 1998). The reported genes for W. bancrofti detection are Ssp1 repeat (Mishra et 
al., 2007; Zhong et al., 1996), LDR repeat (Rao et al., 2006; Rao et al., 2006) and ITSI 
(Nuchprayoon et al., 2005). In addition, a LAMP assay has been developed for B. 
malayi or B. timori detection which can amplify as low as 1 pg of B. malayi genomic 
DNA (Poole at al., 2012). A species specific 114 bp region of mitochondrial 12S rRNA 
genes has been used to differentiate between B. malayi, B. pahangi and D. immitis (Ky 
and Van Chap, 2000) However, the main obstacle with the molecular diagnosis 
methods is that it requires sophisticated laboratory equipment and trained personnels 
to perform the assay and analysis. Besides it also requires several hours to obtain the 
results and they not practical to be used with a large number of samples and for field 
screening.  
 
1.3.6(e) Radiological detection 
Radiological or ultrasonography detection is based on ‘filarial dance sign’ which refers 
to live adult worm inside the lymphatic vessels (Amaral et al., 1994). Advancement in 
imaging technology such as technological refinement using colour and pulse wave 
Doppler allows the imaging of adult worms in deeper lymphatics (Mand et al., 2006; 
Shenoy et al., 2007). Another useful imaging technology called lymphoscintigraphy 
allows the observation of abnormal and dysfunctional lymphatics in infected 
individuals. However, this technique is not suitable for large scale studies.  
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1.3.7 Treatment of lymphatic filariasis 
Basically, there are three different types of drugs available to treat filariasis namely, 
diethylcarbamazine (DEC), ivermectin and albendazole. These drugs kill microfilaria 
and/or adult worms. Diethylcarbamazine is found to be effective against microfilaria, 
but only partially effective against the adult worms and the drug does not act directly 
on the parasite but its action is mediated through the host immune system. Single 
annual administration of 6 mg/kg DEC has been reported to lower the blood 
microfilaria levels markedly and this effect is sustained even at the end of one year 
(Noroes et al., 1997). However, it is reported that a single dose of DEC kills the adult 
worms when they are sensitive to the drug but if they are not sensitive even repeated 
administrations of the drug do not have any effect on the adult worms (Freedman et 
al., 2001). The adverse effects of this drug are only experienced by patients with 
microfilaria and mainly due to their rapid destruction. The symptoms are fever, 
headache, myalgia, sore throat or cough that usually last for 24 to 48 hours. Direct 
adverse effects related to the drug are very rare. 
 Ivermectin acts directly on the microfilaria and effectively keeps the blood 
microfilaria counts at very low levels, even at the end of one year in single annual 
doses of 200–400 mg/kg. The adverse effects of this drug are similar to those produced 
by DEC but then milder due to the slower clearance of the parasitaemia. To date there 
is no evidence to prove ivermectin action against the adult parasite or in tropical 
eosinophilia (Shenoy et al., 1993). This drug is also found to be effective against many 
human intestinal helminths, human ectoparasites like head and body lice and scabies 
(Ottesen et al., 1997).  
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 Another well-known drug which can destroy the adult filarial worms is 
albendazole. The recommended doses are 400 mg twice daily for 2 weeks (Ismail et 
al., 1998). This drug has no direct action against the microfilaria thus does not 
immediately lower the microfilaria counts. However, this drug becomes more 
pronounced in lowering of blood microfilaria levels when it is combined with DEC or 
ivermectin. Only a single dose of 400 mg combined drugs is sufficient to carry out the 
adult worm destructions. Combination of albendazole, either with DEC or ivermectin 
is recommended for the filariasis elimination programme (Ottesen et al., 1997). 
 Treatment using above drugs only effective at the early stages of the disease 
when there is an active filarial infection. Once the development of lymphoedema 
established, there is no permanent cure and treatment as DEC does not seem to reverse 
the existing lymphatic damage (Harinasuta, 1984). There are practices recommeneded 
to alleviate the lymphoedema and to prevent further progression of the swelling. These 
include applying elastocrepe bandage or tailor-made stockings while ambulant, 
keeping the limb elevated at night, after removing the bandage, regular exercising of 
the affected limb, regular light massage of the limb to stimulate the lymphatics and to 
promote flow of lymph towards proximal larger patent vessels; intermittent pneumatic 
compression of the affected limb using single or multicell jackets and heat therapy 
using either wet heat or hot ovens. There are also various surgical procedures available 
like lymph nodo-venous shunts, omentoplasty, excisional surgery and skin grafting but 
the care of the limb is continued for life to prevent recurrence of the swelling. 
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1.4 Global Programme for Elimination of Lymphatic Filariasis (GPELF) 
WHO has reported that more than 20% of the world’s populations are at risk 
of acquiring LF. It is estimated that over 120 million of people in at least 83 countries 
have already been infected and more than 40 million people are incapacitated by the 
disease [The Global Alliance to Eliminate Lymphatic Filariasis (GAELF), 
http://www.filariasis.org]. Over 25 million men suffered from the genital form of the 
disease, while more than 15 million of people suffered from lymphoedema or 
elephantiasis of the leg. Out of these, 90% of the cases are caused by W. bancrofti 
whereas B. malayi which accounts for about 10% (or 13 million) of the infected people, 
especially in South and Southeast Asia, South Korea, and parts of China. In addition, 
Brugia timori is restricted to Timor Leste and a few islands in Indonesia (Michael, 
2000).  
In year 1994, a consultative meeting was held at Universiti Sains Malaysia, 
Penang, to discuss about LF and its Global Control strategies. This was followed by 
the World Health Assembly resolution on elimination of LF as a public health problem 
in 1997. In year 2000, the GAELF was formed in order to support the GPELF. The 
targeted year for world-wide elimination of LF as a public health problem is 2020. The 
elimination strategies are being carried out on a global scale and the main method is 
by interrupting the transmission of infection through mass drug administration 
(MDA); and the second strategy is by alleviation of morbidity caused by the disease 
(http://www.filariasis.org/resources/globalalliance history.htm). The latter focuses on 
decreasing the secondary bacterial and fungal infection of limbs and genitals whose 
lymphatic function has already been compromised by filarial infection (Ottesen, 
2000).  
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The endemic countries of LF and status of MDA are shown in Figure 1.3. A 
pictorial view of the main strategy of GPELF is shown in Figure 1.4. The first step is 
mapping of the endemic areas based on historical data and population testing using the 
then available diagnostic tools namely microscopic examination of thick smears of 
night blood for brugian filariasis and antigen detection test for bacroftian filariasis. 
This is followed by MDA to the entire ‘at risk’ population for at least five years. This 
reduces both infection prevalence and transmission rates to levels below those required 
for sustained transmission (Ottesen et al., 1997; Molyneux, 2001; Ottesen, 2006; Weil 
and Ramzy, 2006). In this way, the level of microfilariae in the population remains 
below that necessary for active transmission. The MDA treatment comprise a single 
dose of two drugs regimens i.e. albendazole 400 mg plus DEC 6 mg/kg or albendazole 
400 mg plus ivermectin 200 μg/kg for a period of 4-6 years which correspond to the 
reproductive life span of the parasite (Ottesen, 2000). Once the infection level fell 
below 1% microfilaremia or 2% antigenemia, transmission assessment surveys (TAS) 
in children 6-7 years are performed to determine whether transmission has been 
interrupted. This is followed by post-MDA surveillance comprising TAS 2 and TAS 
3. Upon passing TAS 3, a dossier is developed which summarizes the LF 
epidemiologic, programmatic, monitoring, evaluation, and findings for the country, 
before validation of the elimination is completed. 
Other than TAS, post-MDA surveillance may also include other activities to 
confirm that transmission interruption such as testing of military recruits, university 
students, blood donors, hospital patients. The status of having validated or certified the 
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Figure 1.3 World endemic countries of lymphatic filariasis and status of mass drug administration (MDA) in these countries, 2015. 
         
         Source: http://gamapserver.who.int/mapLibrary/app/searchResults.aspx 
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Figure 1.4 Strategy of the global programme to eliminate lymphatic filariasis. Mf: Microfilaremia, Ag: Antigen, MDA: Mass drug  
  administration, TAS: Transmission assessment survey. 
 
 
           (Source: Adapted from Ichimori et al., 2014) 
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LF elimination is potentially reversible, thus surveillance activities should still be 
continued post-validation to ensure there is no resurgence or recrudescence of active 
transmission (WHO/HTM/NTD/2016.6). A sensitive and specific field-applicable 
diagnostic tools are required for the various phases of the programme. For TAS 
activities in brugian LF areas, Brugia Rapid and PanLF Rapid are being used. 
Meanwhile, for bancroftian filariasis, rapid antigen detection test (ICT) is used. These 
antibody and antigen rapid detection tests are robust, field-applicable, sensitive, 
specific, sample can be taken at any time of the day, and easy to use and interpret.  
 
1.4.1 The use of Brugia Rapid and PanLF Rapid in GPELF 
Brugia Rapid and PanLF Rapid are two important rapid tests to detect of LF. These 
tests are used by the WHO for transmission assessment surveys of the GPELF. 
 
1.4.1(a) Brugia Rapid  
Brugia Rapid is a rapid cassette test that utilized BmR1 recombinant antigen for the 
detection of brugian filariasis. The BmR1 recombinant antigen is expressed by the 
clone Bm17DIII/pROEXTM HTa/TOP 10 carrying the Brugia malayi gene. It 
comprises 618 bp, coding for a total of 206 amino acid residues and was cloned into 
the multiple cloning site (MCS) of the pROEXTM HT located at 407-1024 bp. The 
molecular mass of the translated BmR1 recombinant protein is approximately 30 kDa.  
 The rapid test is based on the fact that the level of IgG4 antibody to filarial 
antigens is significantly elevated in an active infection (Rahmah et al., 2001). Since it 
is an antibody-based test, it does not require any night blood sampling. In this test, the 
anti-filarial antibodies in patient sera will react with this antigen, followed by binding 
of this complex with monoclonal anti-human IgG4 conjugated to colloidal gold. Thus, 
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samples containing anti-filarial IgG4 antibodies that react specifically to the antigen 
will result in the appearance of a purple-reddish colour at the test line. In the initial 
stages, an ELISA format of the test was developed, known as Brugia-ELISA. 
Evaluation studies on the ELISA demonstrated diagnostic specificity rates of 95.6-
100%, the sensitivity rates of 96-100%, positive predictive values of 75-100%, and the 
negative predictive values of 98.9-100% (Rahmah et al., 2001). However, since this 
test is more suitable for laboratory rather than field use, the test format was changed 
into a rapid immunochromatographic test, which was named as Brugia Rapid. This 
rapid test format is easy to perform, rapid and robust. It does not need any laboratory 
facility, thus useful for field-work in remote areas. 
Evaluation studies of the rapid test have been performed to validate its 
diagnostic sensitivity and specificity. One of the studies showed 97% sensitivity, 99% 
specificity, 97% positive predictive value, and 99% negative predictive value (Rahmah 
et al., 2003).   
 
1.4.1(b) PanLF Rapid 
The PanLF Rapid test utilizes both BmR1 and BmSXP recombinant antigens for the 
detection of specific IgG4 antibody against LF parasites of both bancrotian and brugian 
filariasis. BmSXP recombinant antigen was first derived from the clone isolated from 
a B. malayi adult male worm cDNA library with sera from bancroftian filariasis 
patients. The recombinant strain BmSXP/pROEXTM HT/TOP 10 was constructed with 
the open reading frame (ORF) of SXP1 gene (462 bp). After subcloning into 
pROEXTM HTa expression vector, the size of the gene is 585 bp, which transcribed 
and translated to the BmSXP recombinant protein that has a molecular mass of about 
21.8 kDa.  
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 The BmSXP gene was reported to successfully identify 83% (64/72) of 
bancroftian filariasis patients when tested with IgG4-ELISA (Chandrashekar et al., 
1994). In another study, the same assay showed 100% detection (72/72) (Rao et al., 
2000). In addition, a rapid flow-through IgG immunofiltration test utilizing the 
BmSXP gene was developed and recorded a sensitivity of 91% (30/33) in detecting W. 
bancrofti infection (Lammie et al., 2004).  
 The principle of PanLF Rapid test is similar to the Brugia Rapid but it consists 
of two test lines comprising BmSXP and BmR1 recombinant antigens. The evaluation 
studies of this test have been performed to validate the sensitivity and specificity of 
the rapid test. The average sensitivity and specificity of this rapid test were reported to 
be 96.5% and 99.6% (Rahmah et al., 2007).  
 The BmR1recombinant antigen showed high sensitivity in detecting B. malayi 
infection (98% and 84% respectively) compared to BmSXP recombinant antigen. On 
the other hand, the BmSXP recombinant antigen showed higher sensitivity (95%) in 
detecting W. bancrofti infection as compared to BmR1 (14%). Thus, this rapid test is 
useful for brugian filariasis areas where there are bancroftian filariasis cases. 
 
1.5 Immune response in lymphatic filariasis  
The immune responses to filarial infection encompass a complex network of innate 
and adaptive cells. Interactions of the parasite with these cells result in a spectrum of 
clinical manifestations. Asymptomatic condition may occur to an individual 
harbouring high parasite numbers, with stronger regulatory response while 
immunologically reactive patients with lower numbers of parasites can manifest 
chronic pathology.  
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Principally, innate immune system is the first arm of the immune defense that 
identify infectious agents (Kindt et al., 2007). Next is the adaptive immune system 
with its humoral and cellular responses which are able to respond and remember the 
exogenous encounters. Both these immune systems act in concert to eliminate and 
control infectious diseases. The components of innate immune response are lysozyme, 
interferons, complement and toll-like receptors while those for adaptive immune 
response are antigen presenting cells (APC) and lymphocytes. The main function of 
APCs (macrophages and dendritic cells) is to process and present the antigens to the 
antigen-specific receptors on T cells. Lymphocytes are made up of B lymphocytes also 
called as humoral immune system and T-lymphocytes known as cell-mediated 
immune system (McCullough and Summerfield, 2005). B lymphocytes are the 
essential cells of the immune system stimulated during an immune response to produce 
antibodies. B cells express receptors on their cell surface for antigen recognition and 
binding. However, pathogens can escape the immune systems in several ways such as 
reducing its antigenicity, mimicking the host cell surfaces, selectively suppress the 
immunity, and continual variation of antigen surfaces (Janeway, 2001).  
B cells differentiate from pluripotent hematopoietic stem cells. During early 
embryonic development, the hematopoietic cells migrate into the fetal liver and they 
develop and mature into B cells (Melchers, 2015). B cells can be found in various 
lymphoid organs such as spleen, lymph nodes, tonsils, Peyer’s patches, lungs, 
peritoneal cavity and blood. It typically produces antibody to fight pathogens but there 
is a small subset of B cells known as regulatory B cells that function to supress immune 
responses. These cells secrete a specific cytokine called interleukin-10 (B10) which 
are crucial for controlling inflammation, autoimmunity and limit the normal immune 
